北大醫藥(000788.SZ):醫藥製造板塊目前的產品重點聚焦於抗感染類、鎮痛類和精神類三大領域,以仿製藥為主
格隆匯9月3日丨北大醫藥(000788.SZ)在投資者互動平台表示,公司醫藥製造板塊目前的產品重點聚焦於抗感染類、鎮痛類和精神類三大領域,以仿製藥為主。其中抗感染類產品主要有鹽酸克林黴素棕櫚酸酯顆粒(適用於革蘭氏陽性菌引起的各種感染性疾病,如扁桃體炎、急性支氣管炎、肺炎等)、鹽酸莫西沙星注射液(適用於成人(≥18歲)上呼吸道和下呼吸道感染,如:急性細菌性鼻竇炎、慢性支氣管炎急性發作,社區獲得性肺炎,非複雜性皮膚和皮膚組織感染等)、注射用美羅培南(適用於成人和兒童由單一或多種對美羅培南敏感的細菌引起的感染,如肺炎(包括院內獲得性肺炎)、尿路感染等)等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.